A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response

作者：Manzo Emiliano; Cutignano Adele; Pagano Dario; Gallo Carmela; Barra Giusi; Nuzzo Genoveffa; Sansone Clementina; Ianora Adrianna; Urbanek Konrad; Fenoglio Daniela; Ferrera Francesca; Bernardi Cinzia; Parodi Alessia; Pasquale Giuseppe; Leonardi Antonio; Filaci Gilberto; De Palma Raffaele^*; Fontana Angelo^*

来源：Scientific Reports, 2017, 7(1): 6286.

DOI：10.1038/s41598-017-05969-8

Dendritic Cells (DCs) recognize infectious non-self molecules and engage the adaptive immune system thereby initiating long lasting, antigen-specific responses. As such, the ability to activate DCs is considered a key tool to enhance the efficacy and quality of vaccination. Here we report a novel immunomodulatory sulfolipid named beta-SQDG18 that prototypes a class of natural-derived glycolipids able to prime human DCs by a TLR2/TLR4-independent mechanism and trigger an efficient immune response in vivo. beta-SQDG18 induces maturation of DC with the upregulation of MHC II molecules and co-stimulatory proteins (CD83, CD86), as well as pro-inflammatory cytokines (IL-12 and INF-gamma). Mice immunized with OVA associated to beta-SQDG18 (1:500) produced a titer of anti-OVA Ig comparable to traditional adjuvants. In an experimental model of melanoma, vaccination of C57BL/ 6 mice with beta-SQDG18-adjuvanted hgp10 peptide elicited a protective response with a reduction in tumour growth and increase in survival.

• 出版日期2017-7-24